

17 July 2025

First QCH temporal hollowing study patient receives implant

Highlights

- On 23 May 2025, Osteopore and Queensland Children's Hospital (QCH) launched a clinical study for the treatment of temporal hollowing in 5 paediatric patients.
- Osteopore is delighted to recruit its first patient, who received the implants on 14 July 2025.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: OSX; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the recruitment of its first patient for the Queensland Children's Hospital (QCH) single-arm clinical study to treat temporal hollowing in children following cranial vault remodelling surgery for craniosynostosis.

On 14 July 2025, the patient received the implants.

Temporal hollowing, which is a noticeable depression in the lateral forehead and temple area, can occur in up to 30-40% of patients following cranial vault remodelling surgery. Cranial vault remodelling is a common surgical procedure designed to correct skull contour abnormalities. Craniosynostosis is a congenital condition in which the bones of a child's skull fuse prematurely, potentially leading to an abnormal head shape and neurological complications.

The study will recruit up to 5 patients by the end of 2026 with patient follow-up set to continue for 12 months after surgery. The study is supported by Maddox's Helping Hand Foundation



(MHHF), which supports the Australian Centre for Complex Integrated Surgical Solutions (ACCISS).

The study seeks to assess the feasibility of using a 3D-printed, patient-specific polycaprolactone-tricalcium phosphate (PCL-TCP) onlay scaffold – combined with bone marrow aspirate and platelet-rich fibrin (PRF) – to restore the frontotemporal contour in children who have undergone cranial vault remodelling surgery.

Commenting on the recruitment of the first patient, who has now receiving the implants, CEO Dr Yujing Lim, said:

“We are glad that the collaboration has got off to an early start, as patient recruitment typically takes time.

“With the clinical community moving towards regenerative healing, Osteopore is glad to be among the first movers, especially in providing viable solutions for children.

“We wish all patients a speedy recovery, and look forward to providing more updates as the study progresses,” said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Isaac Stewart
Media & Investor Relations
Purple
E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.



Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

